Tertiary lymphoid structures signature predicts prognosis and clinical benefits from adjuvant chemotherapy and PD-L1 blockade in colorectal adenocarcinoma
{{output}}
Background: Tertiary lymphoid structures (TLS) are emerging biomarkers for enhanced anti-tumoral immunity and treatment efficacy in colorectal cancer (CRC). This study aimed to develop a CRC-specific TLS signature and evaluate it... ...
